Corticobasal Syndrome (CBS) is considered a relatively rare disorder, with an estimated incidence of 1-2 cases per million each year. The exact cause of CBS is unknown, although it is thought to be related to a genetic mutation in the MAPT gene, which is involved in the development and maintenance of white matter. Other potential risk factors include advancing age, head trauma, and autoimmune disorders. CBS is a progressive and ultimately fatal condition, with no approved treatment or cure. Most individuals with CBS will require physical, occupational, and speech therapy to help manage their symptoms, which can include difficulty with coordination, movement, and balance problems, as well as difficulty speaking, understanding, and remembering. Medication may be prescribed to reduce tremors, muscle spasms, and rigidity and to control pain and depression. Botox injections may be recommended to help reduce tremors and rigidity. Surgery may be appropriate in some cases to improve muscle contracture and relieve pressure on the compressed nerves. In addition, supportive treatments, such as nutritional and psychological support, and physical and occupational therapy can help optimize an individual's functional abilities.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States